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ORIGINAL RESEARCH
Aim: To assess the effectiveness of lifestyle measures in the treatment of gastroesophageal
reflux disease (GERD) among adults attending a dietetic practice.
Methods: A retrospective case series of adult patients presenting with GERD to a dietetic
practice over a three year period. The routine lifestyle counselling for treatment of symptoms
of GERD included: not reclining within two to three hours of eating; a diet low in fat; small
frequent meals; avoiding dietary components considered to relax the lower esophageal
sphincter; and avoiding local irritants.
Results: Twenty three cases were included (12 male). Eighteen, (9 female) were referred by
their doctor, 7 (6 female) presented for GERD alone, 7 (4 female) presented for GERD together
with comorbidities, and 9 (1 female) incidentally mentioned GERD during a dietary
consultation for another disorder. Thirteen participants (9 female) had previously undergone
endoscopies, 18 (11 female) were taking medication for GERD, and 19 (7 female) had
comorbidities. Twenty two (10 female) reported an improvement in symptoms with 11/18
taking GERD medication at presentation reducing their medication following treatment.
Conclusions: These results suggest that a more thorough investigation of lifestyle modification
in the treatment of GERD is warranted.
Keywords: lifestyle modification, gastroesophageal reflux disease, symptom reduction, diet,
case series
Introduction
Gastroesophageal reflux disease (GERD) is a common disorder with the classical
symptoms being heartburn and regurgitation, and the less common symptoms
including dysphagia, laryngitis, asthma and chest pain (Isselbacher et al 1994). Early
data (1976) from the US suggested that 7% of the adult population experienced
symptoms daily and around 36% had these symptoms at least once a month (Nebel
et al 1976). These data are likely to be the source of the commonly quoted figure of
almost 40% of adults experiencing these symptoms. However, a more recent study
found that 22% of American adults reported daily symptoms of heartburn and 57%
reported such symptoms at least weekly (Oliveria et al 1999). Due to the differences
in study methodology, it remains unclear whether or not these two studies actually
demonstrate an increase in incidence of GERD over the 20 year interval. In Australia,
results of a telephone survey in New South Wales seeking information about symptoms
of dyspepsia in the previous three months reported a prevalence of 11.4% to 36%
depending on the definition used (Westbrook and Talley 2002). Another Australia-
wide telephone survey found that 37% of respondents reported experiencing heartburn
at least once every 4–6 months (Bolin et al 2000).
While the symptoms of GERD are painful and debilitating for the patient, reflux
is a serious disorder because it is associated with the development of Barrett’s
esophagus and adenocarcinoma of the esophagus and gastric cardia (Cohen and
Effectiveness of lifestyle measures in the
treatment of gastroesophageal reflux disease –
a case series
Madeleine Nowak1
Petra Büttner1
Simone Harrison1
Kym Daniell2
Beverly Raasch2
Rick Speare1
1School of Public Health, Tropical
Medicine and Rehabilitation Sciences,
and 2School of Medicine, North
Queensland Centre for Cancer
Research within the Australian
Institute of Tropical Medicine, James
Cook University, Townsville, Australia
Correspondence: Madeleine Nowak
Skin Cancer Research Group, School of
Public Health and Tropical Medicine,
James Cook University, Townsville, QLD
4811 Australia
Tel +61 7 4796 1748
Fax +61 7 4796 1767
Email Madeleine.Nowak@jcu.edu.auTheapeutics and Clinical Risk Management 2006:2(3) 330
Nowak et al
Parkman 1999). The aetiology of Barrett’s esophagus, a
metaplastic process in which native squamous epithelium
of the distal esophagus is replaced by columnar epithelium,
is unknown, however, clinical and experimental data
implicate GERD (Oberg et al 1998). There is evidence for a
“probably causal” relationship between GERD and
adenocarcinoma of the esophagus, with less clear evidence
of a link between reflux and adenocarcinoma of the gastric
cardia (Lagergren et al 1999).
The incidence of these two cancers (adenocarcinoma of
the esophagus and gastric cardia) is rising faster than that
of any other cancer in the US (DeMeester and DeMeester
1999). In addition, an 8-fold increase in esophageal
adenocarcinoma has been reported in Denmark between
1970 and 1990. This increase was not explained by changes
in classification or diagnosis (Bytzer et al 1999). The
incidence of this cancer is also rising in Australia (Lord et
al 1998). The reason for the increasing incidence of these
cancers is unclear (Falk and Richter 1998). However, the
likely increase in the prevalence of GERD, the increase in
obesity (Mayne and Navarro 2002), and the decline in
Helicobacter pylori colonisation (associated with lower birth
rates and the use of antibiotics, together with a change in
the number and type of variants of the bacterium; Blaser
1999) have been suggested as possible causes.
The mechanisms resulting in GERD are complex and
affected by many factors including the anatomy, genetics
and environment of the individual (Vandenplas and Hassall
2002). Many studies have investigated the effects of
individual dietary components on normal volunteers and
people with GERD (Grande et al 1997; Holloway et al 1997;
Pehl et al 1999, 2001; Meyer et al 2001; Colombo et al
2002). However the results of such studies remain
contradictory.
A review of the earlier literature concluded that lifestyle
modifications have been shown to be effective in the
treatment of GERD (Kitchin and Castel 1991), however,
there have been few well-designed placebo-controlled trials.
Subsequently it has been suggested that many of these
lifestyle changes would not be of benefit in alleviating the
symptoms of GERD, although they would be appropriate
for promoting general health (Galmiche et al 1998). A more
recent review has identified lifestyle recommendations
which are likely to be effective and those with little
supporting evidence (Meining and Classen 2000).
Considerable debate remains about the type of treatment
that should be recommended for the disease, with these
discussions focusing mostly on medication and surgery
(Katz 2002) with little mention of lifestyle modification.
Although conservative therapy (diet, posture, antacids), was
the only treatment for GERD until the advent of the anti-
secretory drugs, the current usage and associated success
rate is unknown. Lifestyle treatment of GERD, in addition
to medication, is recommended in both Australia (Katelaris
et al 2002) and US (DeVault and Castell 1999) and its use
has been documented in studies of general practitioners in
Germany (Meining et al 2002) and Australia (Nowak et al
2005). Such advice has been provided “despite the lack of
scientific evidence” (Meining et al 2002). Furthermore,
participants in a US study investigating the perceived effects
of dietary intake on symptoms of ‘heartburn’ among 2000
individuals identified a number of foods which they believed
precipitated their GERD symptoms (Oliveria et al 1999).
Our clinical experience has implicated similar dietary
factors and suggested that lifestyle modification may reduce
both the symptoms of GERD and patient reliance on
medication to treat this disorder. We retrospectively
evaluated the outcome of this treatment among patients
attending a dietetic practice over a three-year period.
Methods and materials
Participants
All records of adult patients presenting to one private dietetic
practice in Townsville (approximately 130 000 inhabitants),
Australia, between 1 July 1999 and 30 June 2002 were
examined retrospectively in August 2002. Patients who
presented either specifically for the treatment of GERD
symptoms, or who complained of GERD symptoms during
a consultation for another disorder were considered for this
case series. However, only those patients who had attended
an initial dietetic consultation and at least one review were
included in the case series (n=24). One patient, who was
initially included, was subsequently found to have been
prescribed a proton pump inhibitor between the two dietetic
consultations and was therefore excluded.
Intervention
In this practice, all patients who mention heartburn, reflux,
indigestion, or esophagitis are routinely given standardized
dietary and postural advice to alleviate GERD symptoms
as a first line of treatment. This advice includes: not reclining
within two to three hours of eating; a diet low in fat; small
frequent meals; avoiding dietary components considered to
relax the lower esophageal sphincter; and avoiding local
irritants (eg, citrus juices, tomato concentrates, and spices)Therapeutics and Clinical Risk Management 2006:2(3) 331
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(Zeman 1983). It is suggested that these modifications be
adhered to rigorously for one month, followed by a careful
trial of individual components to identify those that should
be excluded in future.
Data collection
Data collected from standard patient records included, sex,
age, height, weight, medication, number of consultations,
time between the first and the last consultation, use of
alcohol and tobacco, exercise level, dietary intake, GERD
symptoms, and comorbidities. As patients had routinely been
asked open ended questions about their reflux symptoms,
their subjective responses were also collected from the
patient records. Patients were not systematically questioned
about prior endoscopies, but for the purposes of this case
series were considered to not have undergone an endoscopy
if it was not mentioned either by the referring doctor or by
the patient during the consultation. Patients were asked to
self-report the frequency and severity of GERD symptoms
and the use of GERD medication.
Statistical analysis
Data were analysed using SPSS for Windows, release 6.3.
Numerical data were described using mean and standard
deviation (SD) or median and interquartile range, as
appropriate. Valid percentages (ie, percentages calculated
by excluding patients with missing information) were given
for categorical variables. Comparisons between gender were
conducted using Chi-square tests (asymptotic and exact),
Fisher’s exact test, t-tests, and non-parametric Wilcoxon
tests, as appropriate. Frequency (none, occasional, less than
daily, daily) and severity (none, mild, moderate, severe) of
symptoms were assessed at initial presentation and after
treatment and were tested for significant changes using exact
paired McNemar tests. Changes in weight and body mass
index were assessed using paired non-parametric Wilcoxon
tests.
Results
A total of 23 patients (12 males) were included in the present
case series. The mean age of these patients was 50.2 years
(SD±12.6 years) with the age distribution being five between
20 and 39 years (4 female), 14 between 40 and 59 years (4
female), and four were at least 60 years old (3 female). The
majority of patients had been referred to the dietetic clinic
by a general practitioner (n=18), had previously had an
endoscopy (n=13), had comorbidities at presentation (n=19),
and were taking medication to relieve GERD symptoms at
presentation (n=18) (Table 1). Females were more likely
than males to present specifically for the treatment of GERD
symptoms (p=0.003), and to have had an endoscopy
(p=0.019) (Table 1). The median alcohol intake was 0.5
standard drinks per day with interquartile range (IQR) 0.05–
2.1 and range 0–20.
More males than females presented with comorbidities
(p=0.037), with the most common comorbidities being
obesity, hyperlipidemia, and hypertension (Table 2). The
majority of the patients were taking prescribed medication
for GERD (n=15) with an additional three taking over the
counter medication for this disease (21 patients with valid
information) (Table 2).
At initial presentation, 13 of 21 patients with valid
information reported daily symptoms of GERD with eight
reporting less frequent symptoms. Of those 21 patients, 18
classified their symptoms as severe and three as moderate.
All but one patient reported a decrease in frequency and/
or severity of symptoms following treatment. This exception
was a 79 year old female with a body mass index of 17.2 kg/
m
2, who presented specifically because of GERD which had
been confirmed at endoscopy. She was taking a proton pump
inhibitor (twice daily) to treat the following symptoms,
which she had had for more than 30 years: nausea; reflux
cough; hoarse voice; regular burping, and flatulence; and
occasional central upper abdominal pain. After a rigorous
trial of the “reflux” diet she reported no change in either
symptoms or the use of medication.
Of the remaining 22 patients, eight (3 female) were
completely symptom free following treatment; eight (5
female) reported only having symptoms of GERD when they
“broke the lifestyle rules”; and five (1 female) reported a
reduction in the frequency and/or severity of their GERD
symptoms following treatment. The specific symptoms of
one patient were not recorded, although she reported marked
improvement at her review appointment. Overall, frequency
(p<0.001) and severity (p=0.002) of symptoms improved
after treatment.
Of the 18 patients for whom weight data were available
at initial and final presentation, 12 had lost weight, 3 had
gained weight, and 3 had remained the same weight, with
the range of weight change being –8 kilograms to
+2 kilograms (Table 1). Weight (p=0.007) was significantly
reduced after treatment. There were no significant
differences in overall improvement (p=0.3330) or frequency
of symptoms (p=0.5908) between patients who had lost
weight during the treatment period and those who had not.Theapeutics and Clinical Risk Management 2006:2(3) 332
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However, patients who had lost weight during the treatment
period were more likely to experience less severe GERD
symptoms than those who had not lost weight (p=0.0365).
Eleven of the 18 patients who were taking GERD
medication at presentation reported a reduction in the use
of GERD medication, although there was no encouragement
given during consultations for patients to reduce either the
type or quantity of GERD medication.
Discussion
The results of this case series suggest that lifestyle
modification may have at least an adjunct role to play in
the treatment of GERD. All but one of the patients
reported a reduction in GERD symptoms following a
rigorous trial of lifestyle modification, with the majority
reporting either no symptoms or only occasional
symptoms for which they could identify the cause. In
addition, more than half the patients who were using
medication for the treatment of GERD had also reduced
the type or frequency of medication.
The literature contains many reports of studies
specifically examining the effects of weight loss, fat intake,
and many of the local irritants incorporated into the advice
given to these patients (Kitchin and Castell 1991). These
studies have examined dietary components individually and
have been conducted rigorously, but the results have not
been consistent (Meining and Classen 2000). The patients
reported here have been treated quite differently, with all
components of lifestyle modification being tested for weeks
rather than individual components being tested for hours.
Furthermore, the endpoint in this work was patient
symptoms whereas most studies have examined the effect
on the lower esophageal sphincter or esophageal pH (Grande
et al 1997; Holloway et al 1997; Pehl et al 1999, 2001;
Colombo et al 2002). It is thus difficult to make any
comparisons between the results obtained from these patients
and the results of previously published studies.
Some reflux symptoms have been shown to be associated
with obesity (Talley et al 2004) and weight loss is generally
considered to reduce the symptoms of GERD (Kitchin and
Table 1 Characteristics of 23 adult patients with gastroesophageal reflux disease (GERD) attending a dietetic practice in
Townsville, Australia
Total Male Female p-value
a
(n=23) (n=12) (n=11)
Baseline characteristics
Mean age (± SD
b) in years 50.2 (12.6) 50.8 (6.1) 49.5 (17.5) p=0.832
Referred by general practitioner  18 (78.2%) 9 (75.0%) 9
d (81.8%) p=1
e
Presented for: 
GERD alone 7 (30.4%) 1 (8.3%) 6 (54.5%)
GERD plus other disease 7 (30.4%) 3 (25.0%) 4 (36.4%)
Incidentally mentioned GERD 9 (39.1%) 8 (66.7%) 1 (9.1%) p=0.003
 e 
History of endoscopy 13 (56.5%) 4 (33.3%) 9 (81.8%) p = 0.019
Using GERD medication at presentation 18 (85.7%) 7 (70.0%) 11 (100%) p=0.090
 e 
Comorbidities at presentation 19 (82.6%) 12 (100%) 7 (63.6%) p=0.037
 e 
Number of patients consuming
>I standard alcoholic drink/day (1 missing) 6 (27.3%) 4 (33.3%) 2 (20.0%) p=0.646
 e
Number of smokers (5 missing) 2 (11.1%) 1 (12.5%) 1 (10.0%) p=1 e 
Median body mass index at initial 30.1 [26.8, 32.5] 30.2 [27.3, 33.5] 28.0 [24.3, 31.6] p=0.201
 e
presentation (kg/m
2) [IQR]
c (5 missing)
 
Treatment
Median number of visits [IQR] 2 [2, 5] 2 [2, 5.25] 3 [2, 5] p=0.608
 e 
Median period of visits [IQR] in months 1.5 [1.0, 7.0] 1.3 [1.0, 5.9] 2 [1.3, 7.0] p=0.347 e 
Outcome
Number of patients with reduction in 19 (90.5%) 11 (91.7%) 8 (88.9%) p=1
 e 
frequency of symptoms 
Number of patients with reduction in 10 (47.6%) 7 (58.3%) 3 (33.3%) p=0.387
 e
severity of symptoms 
 
Decrease in medication (number and/or type)f 11 (73.3%) 3 (60.0%) 8 (80.0%) p=0.560 e 
Median weight change
g (kg) [IQR] –1.5 [–3.6, 0.0] –3.0 [–5.5, –0.5]  –1.0 [–2.8, 0.5] p=0.165
 e 
Notes: 
ap-value relates to comparison between the genders; 
bSD, standard deviation; 
cIQR, inter-quartile range; 
dOne patient presented following a suggestion from a
GP (not her own GP) in a social situation; ep-value result of exact test; 
fData on medication was available for 15 patients at initial presentation and after treatment;
gWeight data available for 18 patients.Therapeutics and Clinical Risk Management 2006:2(3) 333
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Castell 1991; Meining and Classen 2000). Yet, among these
patients, there did not appear to be any difference in the
overall effect of treatment on symptoms between those who
had lost weight, those who had gained weight, or remained
the same. However, those who had lost weight did report a
decrease in the severity, but not frequency, of symptoms.
As there were only a small number of participants in this
study, it is not possible to determine whether weight loss or
the lifestyle changes leading to weight loss were responsible
for the improvement in symptoms. For many of these
patients reducing the symptoms of GERD was far more
important than weight loss, thus weight loss occurred almost
as a consequence of treatment for GERD. Thus careful
questioning about symptoms of GERD by clinicians, and
encouraging treatment of these symptoms by lifestyle
modification may act as a motivator to change to more
healthful dietary behavior.
This case series included a carefully selected group of
patients, either selected by their doctors, or self selected.
The grounds for selection were probably: being prepared to
consider lifestyle modification for treatment of disease;
placing a high priority on health therefore being prepared
to attend a private dietetic practice; and preferring not to
take medication if it could be avoided. Only those patients
who returned for review were included. Hence, these
patients may have been particularly motivated and thus not
representative of the wider population suffering from GERD.
It is certainly possible that a number of patients who derived
no benefit from treatment chose not to return for review
and thus this case series may represent a “best case scenario”.
As the results are based on a small number of cases,
they should be interpreted with caution. Nevertheless, this
case series has shown encouraging results and indicates that
a randomized controlled intervention to fully evaluate the
efficacy of lifestyle modification in the treatment of
symptoms of GERD is probably justified.
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